Highlights
- Healius (ASX:HLS) recorded FY26 underlying Revenue of AUD 1,373.2 million.
- Underlying EBITDA increased 8.1% to AUD 258.6 million.
- The reported net loss widened to AUD 415.6 million.
- Non-cash Impairment charges totalled AUD 332.0 million in FY26.
Healius Limited operates Australian pathology and laboratory services, supporting medical testing for clinicians and patients across its network. On 16 November 2026, Healius (ASX:HLS) traded at AUD 0.588, up 2.17% during the session. Its FY26 Annual Report showed improved underlying revenue and Earnings but a larger statutory net loss, with non-cash impairment charges remaining an important element of the result.
Pathology Operations and Service Network
Healius (ASX:HLS) operates within Australia’s diagnostic testing sector, providing pathology services and associated laboratory infrastructure. Its activities include processing clinical samples and supporting healthcare providers with test results. The group also reports activity through Agilex Biolabs, which contributed to revenue growth in the period.
Operational outcomes depend on sample volumes, medical practitioner demand, labour availability, collection centre coverage and reimbursement. These features make service productivity and cost control relevant measures alongside revenue.
FY26 Revenue and Earnings
For the year ended 30 June 2026, Healius (ASX:HLS) reported underlying revenue of AUD 1,373.2 million, compared with AUD 1,344.5 million in FY25, representing 2.1% growth. Underlying earnings before interest, tax, Depreciation and Amortisation (EBITDA) rose 8.1% to AUD 258.6 million from AUD 239.3 million.
Underlying earnings before interest and tax (EBIT) increased from AUD 17.1 million to AUD 30.2 million. Management associated the results with fee growth in Pathology, Agilex Biolabs revenue and cost-saving activities. It also highlighted improvement in second-half pathology margins, although sector Volume and labour-cost pressures continued.
The company’s full-year disclosures described efforts to improve revenue quality, optimise its network and increase technology-supported productivity. These programmes are intended to address operating efficiency, but their subsequent financial contribution will need to be assessed through reported margins and cash generation.
Statutory Loss and Balance-Sheet Considerations
Healius (ASX:HLS) reported a statutory net loss after tax of AUD 415.6 million for FY26, versus a loss of AUD 151.2 million in FY25. Its annual report included AUD 332.0 million of non-cash impairment charges, compared with AUD 495.2 million in the earlier year. Statutory EBIT was a loss of AUD 328.9 million, compared with a loss of AUD 527.0 million.
Finance costs decreased to AUD 49.1 million from AUD 65.1 million, which the company linked primarily to lower average debt. Income tax expense was AUD 30.9 million, compared with a tax benefit in FY25. The statutory outcome also reflected a loss from discontinued operations in FY26, whereas the prior year included a profit from discontinued operations. These items help explain why changes in the headline net result differ from underlying earnings movements.
The annual report also identified a focus on restoring cash-flow performance, not simply improving underlying earnings. That distinction matters because depreciation, financing costs, tax and non-underlying charges can produce substantially different reported outcomes. Comparing cash generated from operations with expenditure, interest and any restructuring costs in future periods will help establish how much of the underlying improvement is translating into available funds.
Risks to Consider
Healius (ASX:HLS) faces labour costs, testing-volume variability and the need to sustain improvements in network efficiency. Further asset assessments could affect reported statutory results. Financing expenses, Capital requirements and the timing of cost savings also influence the company’s financial position. Underlying earnings measures should be considered alongside reported profit and cash flows.
What to Watch Next
Future reporting will provide evidence on pathology volumes, fee changes, second-half Margin improvement and execution of the efficiency programme. Investors may also follow borrowing costs, cash generation and any additional impairment disclosures. The timing and scale of savings are important when evaluating whether underlying earnings improvement is sustained.
Key Insights
Healius (ASX:HLS) reported higher underlying revenue and EBITDA in FY26 but a wider statutory net loss. Its next reporting periods will help distinguish continuing operational progress from the impact of exceptional and accounting items.
_11_16_2026_11_23_12_237620.jpg)


_11_16_2026_07_52_44_870464.jpg)


Please wait processing your request...